Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral budesonide suspension versus placebo in children and adolescents with eosinophilic esophagitis
MOH_2019-09-12_007103Phase 3Completed
- Sponsor
- Dr. Falk Pharma GmbH
- Start
- May 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of budesonide in eosinophilic esophagitis (EoE) (3 arms), sponsored by Dr. Falk Pharma GmbH. Primary endpoint: Primary efficacy objective. Started May 2019; status: completed.
02
Drugs
budesonide
03
Conditions
eosinophilic esophagitis (EoE)
Beyond the preview
Go deeper on MOH_2019-09-12_007103.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2019-09-12_007103.